Samer Al Hadidi, Associate Professor at the Harold C. Simmons Comprehensive Cancer Center/UT Southwestern Medical Center shared on LinkedIn:
“Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma”
Other articles about antibody therapy on OncoDaily.
You can also read: Multiple Myeloma in 2026: Comprehensive Clinical Updat
